Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease

Mayo Clinic Proceedings

Volumn 82, Issue 5, 2007, Pages 575-582

  Oba, Yuji ^a,b  

^a University of Missouri   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; IPRATROPIUM BROMIDE; SALMETEROL; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SCORING SYSTEM;

EID: 34248140811     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/82.5.575     Document Type: Article

References (35)

1. National Center for Health Statistics. National Health Interview Survey, 2002. Hyattsville, Md: US Dept of Health and Human Services, Centers for Disease Control and Prevention, Division of Health Interview Statistics; 2002.
2. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. MMWR Surveill Summ. 2002;51:1-16.
3. National Heart Lung and Blood Institute. 2004 NHLBI Morbidity and Mortality Chartbook. Bethesda, Md: US Dept of Health and Human Services, National Institutes of Health; 2004.
4. Global Initiative for Chronic Obstructive Lung Disease. 2003 Update: Workshop Report, Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Available at: www.goldcopd .com/GuidelineItem.asp?intID=991. Accessed March 23, 2007.
5. Kind P. The EuroQoL instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. New York, NY: Lippincott-Raven Publishers; 1996:191-201.
6. Ståhl E, Lindberg A, Jansson S-A, et al. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes. 2005;3:56.
7. Red Book (Red Book Drug Topics). Montvale, NJ: Thomson; 2005.
8. Friedman M, Menjoge SS, Anton SF, Kesten S. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD). Pharmacoeconomics. 2004;22:741-749.
9. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005;143: 317-326.
10. Individual DRG Report Description: Chronic Obstructive Pulmonary Disease-Clinical, Financial & Statistical Data. Available at: http://solucient .ecnext.com/coms2/drgdesc_088. Accessed March 23, 2007.
11. Pennachio DL. Exclusive survey: fees & reimbursements. Med Econ. 2003;80:96-98, 104-106, 109.
12. Wilson L, Devine EB, So K. Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Respir Med. 2000; 94:204-213.
13. Sin DD, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med. 2004;116:325-331.
14. CPI inflation calculator. Available at: http://data.bls.gov/cgi-bin/ cpicalc.pl. Accessed March 23, 2007.
15. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217-224.
16. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD [published correction appears in Thorax. 2005;60:105]. Thorax. 2003;58:399-404.
17. Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD [published correction appears in Eur Respir J. 2006;27:1076]. Eur Respir J. 2006;27:547-555.
18. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002;122:47-55.
19. Chapman KR, Arvidsson P, Chuchalin AG, et al. The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial: chronic obstructive pulmonary disease. Can Respir J. 2002;9:178-185.
20. Stockley RA, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax. 2006;61:122-128.
21. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997;155:1283-1289.
22. Briggs DD Jr, Covelli H, Lapidus R, Bhattycharya S, Kesten S, Cassino C. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther. 2005;18:397-404. Epub 2005 Apr 25.
23. van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ, Dutch Tiotropium Study Group. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax. 2000;55:289-294.
24. Vincken W, van Noord JA, Greefhorst AP, et al, Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 2002;19:209-216.
25. Oostenbrink JB, Rutten-yan Molken MP, Al MJ, van Noord JA, Vincken W. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J. 2004;23:241-249.
26. VHA Pharmacy Benefits Management Strategic Healthcare Group and Medical Advisory Panel. National PBM Drug Monograph: Tiotropium (Spiriva®). Available at: www.pbm.va.gov/monograph/23876yTiotropium.pdf. Accessed March 23, 2007.
27. Cohen DJ, Bakhai A, Shi C, et al, SIRIUS Investigators. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation. 2004 Aug 3; 110:508-514. Epub 2004 Jul 19.
28. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002;287:2542-2551.
29. Eisner MD, Yelin EH, Trupin L, Blanc PD. The influence of chronic respiratory conditions on health status and work disability. Am J Public Health. 2002;92:1506-1513.
30. Rossi A, Kristufek P, Levine BE, et al, Formoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study Group. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest. 2002;121:1058-1069.
31. Dahl R, Greefhorst LA, Nowak D, et al, Formoterol in Chronic Obstructive Pulmonary Disease I (FICOPD I) Study Group. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:778-784.
32. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease [published correction appears in Eur Respir J. 2004;24: 1075]. Eur Respir J. 2003;22:912-919.
33. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease [published correction appears in Eur Respir J. 2003;21:912]. Eur Respir J. 2003;21:74-81.
34. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
35. Nord, E. Cost-Value Analysis in Health Care: Making Sense Out of QALYs. Cambridge University Press: Cambridge, UK; 1999.